<DOC>
	<DOCNO>NCT00295594</DOCNO>
	<brief_summary>To compare efficacy safety two regimen contain tacrolimus minimal steroid together either monoclonal anti-IL2R antibody ( daclizumab ) mycophenolate mofetil .</brief_summary>
	<brief_title>Comparing Efficacy &amp; Safety Tacrolimus With/Without MMF Monoclonal Anti-IL2R Antibody Liver Transplantation .</brief_title>
	<detailed_description>This prospective randomise trial combine MMF tacrolimus avoids steroid immunosuppressive maintenance could demonstrate alternative current immunosuppressive regimen . There evidence reduce steroid usage could decrease onset diabetes mellitus , hypertension viral infection combine high efficacy patient graft survival . Since use MMF liver transplantation become alternative rescue setting could contribute steroid-free immunosuppressive approach .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients 18 year age old undergo primary orthotopic liver split liver allograft transplantation eligible study . Patients receive liver transplant cadaveric heartbeating donor compatible AB0 blood type include . Recipient auxiliary graft Patient require initial sequential parallel therapy immunosuppressive antibody preparation ( ) . Patient require ongoing dose corticosteroid . Patient exhibit symptom , previous history neoplastic disease Patient donor know HIV positive . Patient allergic intolerant study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>